Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond

Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

Volumn 2013, Issue , 2013, Pages 189-200

  Ahmed, Wesam ^a   Van Etten, Richard A ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDE DERIVATIVE; IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

AUSTRALIA; CANCER STEM CELL; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; ENZYMOLOGY; EPIDEMIOLOGY; FRANCE; HUMAN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MORTALITY; PATHOLOGY; PHILADELPHIA 1 CHROMOSOME; SURVIVAL RATE;

AUSTRALIA; BENZAMIDES; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FRANCE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASTIC STEM CELLS; PHILADELPHIA CHROMOSOME; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SURVIVAL RATE;

EID: 84902585618     PISSN: None     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation-2013.1.189     Document Type: Review

References (0)